AbbVie set to acquire Nimble Therapeutics for $200 million
The acquisition is based on a press release statement and is subject to various risks and uncertainties, which could potentially affect the anticipated benefits of the transaction. AbbVie (NYSE:), a company with a broad impact across several therapeutic areas, including immunology and oncology, aims to integrate Nimble’s expertise to bolster its position in the development of treatments for serious health issues. Based on InvestingPro Fair Value analysis, AbbVie’s stock is currently trading near its Fair Value, suggesting appropriate market pricing for this strategic move. Investors can access detailed valuation metrics and 10+ additional ProTips through InvestingPro’s comprehensive research platform. Based on InvestingPro Fair Value analysis, AbbVie’s stock is currently trading near its Fair Value, suggesting appropriate market pricing for this strategic move. Investors can access detailed valuation metrics and 10+ additional ProTips through InvestingPro’s comprehensive research platform. The acquisition, announced Today, includes Nimble’s leading investigational oral peptide IL23R inhibitor currently in preclinical development for psoriasis, as well as other novel oral peptide assets targeting various autoimmune diseases.
The acquisition is based on a press release statement and is subject to various risks and uncertainties, which could potentially affect the anticipated benefits of the transaction. AbbVie, a company with a broad impact across several therapeutic areas, including immunology and oncology, aims to integrate Nimble’s expertise to bolster its position in the development of treatments for serious health issues. Based on InvestingPro Fair Value analysis, AbbVie’s stock is currently trading near its Fair Value, suggesting appropriate market pricing for this strategic move. Investors can access detailed valuation metrics and 10+ additional ProTips through InvestingPro’s comprehensive research platform.
Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research at AbbVie, highlighted the potential of the acquisition to address unmet medical needs in autoimmune diseases. Jigar Patel, Ph.D., founder and CEO of Nimble Therapeutics, expressed confidence in AbbVie’s ability to further the reach of Nimble’s innovative oral therapies.
The preclinical IL23R inhibitor is a promising oral therapy for psoriasis and inflammatory bowel disease (IBD), targeting a clinically validated therapeutic point. The closing of the deal is contingent upon customary conditions, including the Hart-Scott-Rodino Antitrust Improvements Act waiting period.
Nimble’s backers include Telegraph Hill Partners and Roche Ventures, signaling strong foundational support for the company’s pipeline and technology.
The acquisition is based on a press release statement and is subject to various risks and uncertainties, which could potentially affect the anticipated benefits of the transaction. AbbVie, a company with a broad impact across several therapeutic areas, including immunology and oncology, aims to integrate Nimble’s expertise to bolster its position in the development of treatments for serious health issues.
In other recent news, pharmaceutical giant AbbVie has reported a series of significant developments. The company has finalized the acquisition of Aliada Therapeutics, adding a promising Alzheimer’s disease therapy, ALIA-1758, to its neuroscience pipeline. This acquisition is seen as a strategic step to strengthen AbbVie’s position in the neuroscience field.
AbbVie has also reported positive results from its Phase 3 TEMPO-2 trial of tavapadon, a potential treatment for early Parkinson’s disease. The trial met its primary and key secondary endpoints, demonstrating significant improvement in motor function in patients treated with tavapadon.
On the financial front, AbbVie’s Q3 revenues reached nearly $14.5 billion, surpassing expectations with an operational growth of 4.9%. The company raised its full-year revenue guidance by $500 million and adjusted EPS guidance to $10.90-$10.94.
In terms of analyst notes, TD Cowen has named AbbVie as a top pick for 2025, maintaining a positive stance on the pharmaceutical company with a buy stock rating. Leerink Partners also upgraded AbbVie’s stock to Outperform, citing strong revenue and earnings per share growth, while BMO Capital Markets maintained its Outperform rating despite a setback in clinical trials.
In addition to these developments, AbbVie has entered into a strategic partnership with EvolveImmune Therapeutics to develop multispecific biologics targeting cancer, with EvolveImmune receiving $65 million upfront in fees and equity investment from AbbVie. These are all recent developments that indicate ongoing advancements and growth at AbbVie.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
